Annual Securities Report — FY2025
What KAKEN PHARMACEUTICAL CO.,LTD. reported for the period from 2025-04-01 to 2026-03-31.
Filed 2026-06-25View the original on EDINET
How much it says
63Detailed
What moved here
46named for the first time
Its own wording
44terms
Which filing this is
32/ 32newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
For the current period, revenue was ¥76,871 million, operating loss was ¥899 million and net income attributable to owners of the parent was ¥2,144 million, resulting in lower revenue and lower profit. The filing also states that the provisional accounting treatment for the business combination with アーディ社 was finalized during the consolidated fiscal year.
Komori's summary of this document, not the document's own words.63Detailed
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 37 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
68
Detailed
70
Detailed
62
Detailed
17
Almost nothing
100
Very detailed
68
Detailed
50
Typical
60
Detailed
55
Typical
50
Typical
R&D spend206億円Money spent making new things.
Cash left over-148億円Cash from the business, less what went into equipment.
Spent on equipment37億円Plants, machines — things meant to last.
Employees1,086Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.